Report cover image

Bullous Pemphigoid Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Publisher Global Markets Direct
Published Nov 30, 2022
Length 55 Pages
SKU # GMD17776502

Description

Bullous Pemphigoid Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bullous Pemphigoid - Drugs In Development, 2022, provides an overview of the Bullous Pemphigoid (Dermatology) pipeline landscape.

Bullous pemphigoid is a chronic, inflammatory, subepidermal, blistering disease. The disease can be fatal, particularly in patients who are debilitated. Symptoms include intense itching and burning sensation of the skin. It most commonly occurs in people older than age 60. Treatment includes anti-inflammatory and immunosuppressant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bullous Pemphigoid - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Bullous Pemphigoid (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bullous Pemphigoid (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Bullous Pemphigoid and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 6, 1, 4, 1 and 1 respectively.

Bullous Pemphigoid (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bullous Pemphigoid (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Bullous Pemphigoid (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bullous Pemphigoid (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bullous Pemphigoid (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bullous Pemphigoid (Dermatology)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bullous Pemphigoid (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bullous Pemphigoid (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

55 Pages
Introduction
Global Markets Direct Report Coverage
Bullous Pemphigoid – Overview
Bullous Pemphigoid – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Bullous Pemphigoid – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bullous Pemphigoid – Companies Involved in Therapeutics Development
Akari Therapeutics Plc
Alkahest Inc
Alpine Immune Sciences Inc
Amgen Inc
Argenx SE
ARTham Therapeutics Inc
Immungenetics AG
Innate Pharma SA
Kyowa Kirin Co Ltd
Regeneron Pharmaceuticals Inc
Sanofi
Satellos Bioscience Inc
SFA Therapeutics Inc
viDA Therapeutics Inc
Bullous Pemphigoid – Drug Profiles
ALPN-303 – Drug Profile
apremilast – Drug Profile
ART-648 – Drug Profile
avdoralimab – Drug Profile
benralizumab – Drug Profile
bertilimumab – Drug Profile
dimethyl fumarate – Drug Profile
dupilumab – Drug Profile
efgartigimod alfa – Drug Profile
lazucirnon hydrochloride – Drug Profile
RGRN-305 – Drug Profile
SFA-003 – Drug Profile
Small Molecules for Dermatology, Immunology, Metabolic and CNS Disorders – Drug Profile
sutimlimab – Drug Profile
Synthetic Coversin – Drug Profile
VTI-1002 – Drug Profile
Bullous Pemphigoid – Dormant Projects
Bullous Pemphigoid – Discontinued Products
Bullous Pemphigoid – Product Development Milestones
Featured News & Press Releases
Jan 15, 2021: ARTham Therapeutics presents phase I results for ART-648 at ASCPT 2021 Annual Meeting
Mar 30, 2020: ART-648 program was selected as a drug discovery project for orphan diseases to be supported by AMED
Jan 20, 2020: AstraZeneca studies Fasenra in three new trials for skin diseases
Sep 11, 2018: Bertilimumab granted Fast Track Designation for the treatment of Bullous Pemphigoid
Aug 20, 2018: Bertilimumab granted Orphan Drug Designation for the treatment of Bullous Pemphigoid
Jul 30, 2018: Immune Pharmaceuticals receives positive opinion for orphan drug designation in the European Union for Bertilimumab for the treatment of bullous pemphigoid
May 15, 2018: Immune Pharmaceuticals Presents Updated Positive Results from Phase 2 Trial of Bertilimumab in Bullous Pemphigoid
Mar 12, 2018: Immune Pharmaceuticals Announces Acceptance of Abstract at 2018 Pre-IID Pemphigus and Pemphigoid Symposium
Sep 27, 2017: Immune Pharmaceuticals Announces Positive Results from Ongoing Phase 2 Trial of Bertilimumab in Bullous Pemphigoid
Aug 28, 2017: Immune Pharmaceuticals Provides update on bertilimumab
Feb 28, 2017: Immune Pharmaceuticals Reports Encouraging Preliminary Data with Bertilimumab in an Open Label Phase 2 Study in the Rare Dermatological Auto-Immune Disease, Bullous Pemphigoid
Jun 14, 2016: Immune Pharmaceuticals Expands its Bertilimumab Phase II Clinical Trial in Bullous Pemphigoid to Six Academic Institutions in the United States
Nov 09, 2015: Immune Pharmaceuticals Announces FDA Acceptance of Investigational New Drug (IND) Application in the U.S. for Bertilimumab for the Treatment of Bullous Pemphigoid
Oct 07, 2015: Immune Pharmaceuticals Submits Investigational New Drug Application in the U.S. for its Lead Product Candidate Bertilimumab for the Treatment of Bullous Pemphigoid
Jul 13, 2015: Immune Pharmaceuticals to present bertilimumab at The International Eosinophil Society workshop on Personalized Medicine
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for Bullous Pemphigoid, 2022
Table 2: Number of Products under Development by Companies, 2022
Table 3: Products under Development by Companies, 2022
Table 4: Number of Products by Stage and Target, 2022
Table 5: Number of Products by Stage and Mechanism of Action, 2022
Table 6: Number of Products by Stage and Route of Administration, 2022
Table 7: Number of Products by Stage and Molecule Type, 2022
Table 8: Bullous Pemphigoid – Pipeline by Akari Therapeutics Plc, 2022
Table 9: Bullous Pemphigoid – Pipeline by Alkahest Inc, 2022
Table 10: Bullous Pemphigoid – Pipeline by Alpine Immune Sciences Inc, 2022
Table 11: Bullous Pemphigoid – Pipeline by Amgen Inc, 2022
Table 12: Bullous Pemphigoid – Pipeline by Argenx SE, 2022
Table 13: Bullous Pemphigoid – Pipeline by ARTham Therapeutics Inc, 2022
Table 14: Bullous Pemphigoid – Pipeline by Immungenetics AG, 2022
Table 15: Bullous Pemphigoid – Pipeline by Innate Pharma SA, 2022
Table 16: Bullous Pemphigoid – Pipeline by Kyowa Kirin Co Ltd, 2022
Table 17: Bullous Pemphigoid – Pipeline by Regeneron Pharmaceuticals Inc, 2022
Table 18: Bullous Pemphigoid – Pipeline by Sanofi, 2022
Table 19: Bullous Pemphigoid – Pipeline by Satellos Bioscience Inc, 2022
Table 20: Bullous Pemphigoid – Pipeline by SFA Therapeutics Inc, 2022
Table 21: Bullous Pemphigoid – Pipeline by viDA Therapeutics Inc, 2022
Table 22: Bullous Pemphigoid – Dormant Projects, 2022
Table 23: Bullous Pemphigoid – Discontinued Products, 2022
List of Figures
Figure 1: Number of Products under Development for Bullous Pemphigoid, 2022
Figure 2: Number of Products under Development by Companies, 2022
Figure 3: Number of Products by Top 10 Targets, 2022
Figure 4: Number of Products by Stage and Top 10 Targets, 2022
Figure 5: Number of Products by Top 10 Mechanism of Actions, 2022
Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Figure 7: Number of Products by Routes of Administration, 2022
Figure 8: Number of Products by Stage and Routes of Administration, 2022
Figure 9: Number of Products by Molecule Types, 2022
Figure 10: Number of Products by Stage and Molecule Types, 2022

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us